| 1 |
31395751 | Phase Ib Study of Combination Therapy with MEK Inhibitor Binimetinib and Phosphatidylinositol 3-Kinase Inhibitor Buparlisib in Patients with Advanced Solid Tumors with RAS/RAF Alterations. | 2020 Jan |
1 |
| 2 |
30715997 | Buparlisib in Patients With Recurrent Glioblastoma Harboring Phosphatidylinositol 3-Kinase Pathway Activation: An Open-Label, Multicenter, Multi-Arm, Phase II Trial. | 2019 Mar 20 |
1 |
| 3 |
27831000 | Targeted therapies for the treatment of non-small-cell lung cancer: Monoclonal antibodies and biological inhibitors. | 2017 Apr 3 |
1 |
| 4 |
28276440 | Deconvolution of Buparlisib's mechanism of action defines specific PI3K and tubulin inhibitors for therapeutic intervention. | 2017 Mar 9 |
2 |
| 5 |
26846842 | BKM-120 (Buparlisib): A Phosphatidyl-Inositol-3 Kinase Inhibitor with Anti-Invasive Properties in Glioblastoma. | 2016 Feb 5 |
3 |